These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 17477809)

  • 21. Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.
    Biswas S; Eisen T
    Nat Rev Clin Oncol; 2009 Aug; 6(8):478-87. PubMed ID: 19546865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Check point inhibitors a new era in renal cell carcinoma treatment.
    Alsharedi M; Katz H
    Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Immunotherapies for Renal Cell Carcinoma.
    Al-Marrawi MY; Holder SL
    Curr Mol Pharmacol; 2016; 9(3):252-263. PubMed ID: 26177641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging immunotherapy in advanced renal cell carcinoma.
    Mendiratta P; Rini BI; Ornstein MC
    Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
    Kirner A; Mayer-Mokler A; Reinhardt C
    Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet?
    Guida M; Colucci G
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi149-52. PubMed ID: 17591810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer.
    Ranieri E; Gigante M; Storkus WJ; Gesualdo L
    Clin Exp Immunol; 2007 Mar; 147(3):395-400. PubMed ID: 17302887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy and targeted therapy combinations in renal cancer.
    McDermott DF
    Curr Clin Pharmacol; 2011 Aug; 6(3):207-13. PubMed ID: 21827391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
    Godwin JL; Zibelman M; Plimack ER; Geynisman DM
    Discov Med; 2014 Dec; 18(101):341-50. PubMed ID: 25549705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between tumor-infiltrating T lymphocytes and clinical response after reduced-intensity allogeneic hematopoietic stem cell transplantation for advanced renal cell carcinoma: a single center prospective study.
    Ishiyama K; Takami A; Suzuki S; Konaka H; Namiki M; Ooi A; Nakao S
    Jpn J Clin Oncol; 2009 Dec; 39(12):807-12. PubMed ID: 19770130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
    Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M
    Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in immune-based therapies of renal cell carcinoma.
    Lam JS; Belldegrun AS; Figlin RA
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal cell carcinoma: recent progress and future directions.
    Mulders P; Figlin R; deKernion JB; Wiltrout R; Linehan M; Parkinson D; deWolf W; Belldegrun A
    Cancer Res; 1997 Nov; 57(22):5189-95. PubMed ID: 9371523
    [No Abstract]   [Full Text] [Related]  

  • 36. Allogeneic stem cell transplantation for renal cell carcinoma.
    Bregni M; Herr W; Blaise D;
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):901-11. PubMed ID: 21707287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.
    Laurell A; Lönnemark M; Brekkan E; Magnusson A; Tolf A; Wallgren AC; Andersson B; Adamson L; Kiessling R; Karlsson-Parra A
    J Immunother Cancer; 2017; 5():52. PubMed ID: 28642820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.
    Braun DA; Bakouny Z; Hirsch L; Flippot R; Van Allen EM; Wu CJ; Choueiri TK
    Nat Rev Clin Oncol; 2021 Apr; 18(4):199-214. PubMed ID: 33437048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TroVax(®) vaccine therapy for renal cell carcinoma.
    Zhang RT; Bines SD; Ruby C; Kaufman HL
    Immunotherapy; 2012 Jan; 4(1):27-42. PubMed ID: 22149999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy of kidney cancer.
    Grivas PD; Redman BG
    Curr Clin Pharmacol; 2011 Aug; 6(3):151-63. PubMed ID: 21827390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.